11/20
07:17 am
imtx
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Low
Report
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
11/19
12:46 pm
imtx
Immatics (NASDAQ: IMTX) had its price target lowered by analysts at Bank of America Co. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Immatics (NASDAQ: IMTX) had its price target lowered by analysts at Bank of America Co. from $16.00 to $15.00. They now have a "buy" rating on the stock.
11/18
01:40 pm
imtx
What Makes Immatics (IMTX) a New Buy Stock [Yahoo! Finance]
Medium
Report
What Makes Immatics (IMTX) a New Buy Stock [Yahoo! Finance]
11/18
07:12 am
imtx
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME [Yahoo! Finance]
Medium
Report
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME [Yahoo! Finance]
11/18
07:00 am
imtx
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Medium
Report
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
11/8
05:00 pm
imtx
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Low
Report
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
11/5
12:13 pm
imtx
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Low
Report
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
10/23
07:21 am
imtx
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% [Yahoo! Finance]
Low
Report
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% [Yahoo! Finance]
10/10
08:50 pm
imtx
Immatics Announces Pricing of $150 Million Public Offering
Low
Report
Immatics Announces Pricing of $150 Million Public Offering
10/10
07:30 am
imtx
Immatics Announces Proposed $150 Million Public Offering
High
Report
Immatics Announces Proposed $150 Million Public Offering
10/10
06:30 am
imtx
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
High
Report
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
10/7
08:10 am
imtx
Immatics (NASDAQ: IMTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $19.00 price target on the stock.
Low
Report
Immatics (NASDAQ: IMTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $19.00 price target on the stock.
10/4
09:00 am
imtx
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Low
Report
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
9/17
07:43 am
imtx
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific [Yahoo! Finance]
Low
Report
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific [Yahoo! Finance]
9/16
05:32 am
imtx
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update [Yahoo! Finance]
Low
Report
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update [Yahoo! Finance]
9/16
05:25 am
imtx
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
Low
Report
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
9/6
07:00 am
imtx
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
Low
Report
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
9/5
12:10 pm
imtx
Immatics (NASDAQ: IMTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Immatics (NASDAQ: IMTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.